Lifileucel Yields Durable Responses in Pretreated Advanced Melanoma

Source: OncLive, April 2021

The tumor-infiltrating lymphocyte (TIL) therapy lifileucel (LN-144) was found to elicit durable responses in patients with advanced melanoma who were previously treated with an immune checkpoint inhibitor, according to data from a cohort of the phase 2 C-144-02 trial (NCT02360579) presented during the virtual AACR Annual Meeting 2021.1

READ THE ORIGINAL FULL ARTICLE
Menu